SAZ.DE - STADA Arzneimittel Aktiengesellschaft

XETRA - XETRA Delayed Price. Currency in EUR
80.40
-0.07 (-0.09%)
At close: 5:35PM CET
Stock chart is not supported by your current browser
Previous Close80.47
Open80.76
Bid0.00 x 5000
Ask0.00 x 28500
Day's Range80.14 - 80.76
52 Week Range46.31 - 83.91
Volume71,816
Avg. Volume45,787
Market Cap4.995B
BetaN/A
PE Ratio (TTM)52.79
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters15 days ago

    Nestle, Stada prepare rival bids for Germany's Merck consumer health - sources

    LONDON/FRANKFURT, Nov 30 (Reuters) - Swiss food giant Nestle and the private equity owners of German drug firm Stada are both preparing tentative bids for Merck KgaA's consumer health unit, several sources told Reuters. Merck's financial adviser JPMorgan has invited bids for the business, which is valued at about 4 billion euros ($4.8 billion), ahead of a Dec. 15 deadline, the sources said. Nestle is widely seen as a natural buyer for the maker of Seven Seas vitamins and Bion nutritional supplements, after previous talks to set up a consumer joint venture with Merck fell through over the summer.

  • Capital Cubelast month

    STADA Arzneimittel AG – Value Analysis (XETRA:SAZ) : November 13, 2017

    Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives STADA Arzneimittel AG a score of 31. Our analysis is based on comparing STADA Arzneimittel AG with the following peers – Biotest AG Pref, Merck KGaA, Chemical Works of Gedeon Richter Plc, Bayer AG and MorphoSys AG (BIO3-DE, MRK-DE, RIG2-DE, BAYN-DE and MOR-DE). Investment Outlook STADA Arzneimittel ... Read more (Read more...)

  • STADA Arzneimittel AG breached its 50 day moving average in a Bearish Manner : SAZ-DE : November 10, 2017
    Capital Cubelast month

    STADA Arzneimittel AG breached its 50 day moving average in a Bearish Manner : SAZ-DE : November 10, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for STADA Arzneimittel AG. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Booming European Loan Market Tops 2016 on Chunky M&A Deals
    Bloomberg3 months ago

    Booming European Loan Market Tops 2016 on Chunky M&A Deals

    Leveraged loan issuance in Europe this year has surpassed the whole of 2016, after a series of major mergers and acquisitions added fuel to the booming market.

  • Reuters3 months ago

    CVC, others explore sale of drugmaker Alvogen - Bloomberg

    CVC Capital Partners and other private equity owners are exploring options for generic drugmaker Alvogen, including a sale, which could be valued at about $4 billion, Bloomberg reported on Tuesday. Alvogen's controlling shareholders have held talks with Shanghai Pharmaceuticals Holding Co for the sale of Alvogen's U.S. business, Bloomberg said, citing people familiar with the matter. The drugmaker will keeps its Asian and central European operations, Bloomberg reported.

  • The Wall Street Journal3 months ago

    [$$] Giant Bond Issued to Finance Stada Deal

    The holding company Bain Capital and Cinven set up to buy phamaceuticals company Stada Arzneimittel AG issued €1.08 billion ($1.29 billion) of bonds as part of the financing package for the takeover.

  • Moody's3 months ago

    Nidda Healthcare Holding AG -- Moody's assigns (P)B2 CFR to Nidda BondCo GmbH, outlook stable

    Rating Action: Moody's assigns B2 CFR to Nidda BondCo GmbH, outlook stable. Global Credit Research- 07 Sep 2017. Frankfurt am Main, September 07, 2017-- Moody's Investors Service, has today assigned a ...

  • Reuters3 months ago

    Bain, Cinven give in to Elliott's demand for higher Stada buyout

    Buyout groups Bain Capital and Cinven said they would propose to Stada's management to offer minority shareholders cash compensation of 74.40 euros per share, giving in to pressure from activist investor Elliott. Bain and Cinven last month won control of German generic drug maker Stada with a sweetened 5.3 billion-euro ($6.3 billion) bid, in the largest private-equity funded takeover of a German listed company, offering 66.25 euros per share. Elliott Management had said on Thursday, however, that it wanted at least 74.40 euros per share for its stake, which most recently stood at 13.3 percent, or 15.2 percent when taking stock options into account.

  • Reuters4 months ago

    Elliott demands at least 74.40 euros/share for its Stada stake

    Activist investor Elliott Management said on Thursday it wanted at least 74.40 euros per share for its stake in Stada as private equity firms Bain Capital and Cinven seek to tighten their grip on the German generic drugmaker. Bain and Cinven this month won control of Stada with a sweetened 5.3 billion-euro ($6.3 billion) bid, in the largest private-equity funded takeover of a German listed company, offering 66.25 euros per share.

  • Reuters4 months ago

    Elliott demands at least 74.40 eur/shr for Stada minority stakeholders

    Activist investors Elliott said it would not support a domination agreement between Stada and its buyers if compensation for minority shareholders was not at least 74.40 euros per share. Bain Capital and ...

  • STADA Arzneimittel AG – Value Analysis (XETRA:SAZ) : August 21, 2017
    Capital Cube4 months ago

    STADA Arzneimittel AG – Value Analysis (XETRA:SAZ) : August 21, 2017

    Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives STADA Arzneimittel AG a score of 38. Our analysis is based on comparing STADA Arzneimittel AG with the following peers – Biotest AG Pref, Merck KGaA, Chemical Works of Gedeon Richter Plc, Bayer AG and MorphoSys AG (BIO3-DE, MRK-DE, RIG2-DE, BAYN-DE and MOR-DE). Investment Outlook STADA Arzneimittel ... Read more (Read more...)

  • STADA Arzneimittel AG breached its 50 day moving average in a Bullish Manner : SAZ-DE : August 21, 2017
    Capital Cube4 months ago

    STADA Arzneimittel AG breached its 50 day moving average in a Bullish Manner : SAZ-DE : August 21, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for STADA Arzneimittel AG. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Bain, Cinven Clear First Stada Obstacle as Holdouts Await
    Bloomberg4 months ago

    Bain, Cinven Clear First Stada Obstacle as Holdouts Await

    Bain Capital and Cinven barely succeeded at winning over enough shareholders to move forward with their takeover of Germany’s Stada Arzneimittel AG. Now they have to convince the holdouts.

  • Elliott Makes Its $33 Billion Presence Felt in Europe
    Bloomberg4 months ago

    Elliott Makes Its $33 Billion Presence Felt in Europe

    From mining to chemicals to generic drugs, billionaire Paul Singer’s investment vehicle Elliott Management Corp. is making its $33 billion presence felt in Europe this week.

  • How to Spend $1.6 Trillion? Start With an Obscure German Drugmaker
    Bloomberg4 months ago

    How to Spend $1.6 Trillion? Start With an Obscure German Drugmaker

    The battle for Stada shows private equity’s growing haste to buy.

  • Reuters4 months ago

    Stada warns retail tender rate even lower than before

    Stada on Monday warned that even fewer retail investors have so far tendered their shares in the planned takeover of the German generic drugmaker than at the same stage during the previous, failed attempt to get a deal done. "The tender rate among retail investor is much lower than during the first attempt and much lower than we expected. Stada, which is roughly 25-percent owned by retail shareholders, earlier on Monday said 34.1 percent of shares had been tendered by 1600 GMT on Friday.

  • STADA Arzneimittel AG breached its 50 day moving average in a Bearish Manner : SAZ-DE : August 10, 2017
    Capital Cube4 months ago

    STADA Arzneimittel AG breached its 50 day moving average in a Bearish Manner : SAZ-DE : August 10, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for STADA Arzneimittel AG. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • GuruFocus.com5 months ago

    Longleaf Partners Comments on STADA Arzneimittel

    Guru stock highlight

  • Stada's CEO Says Top Line Growth Moved by New Products
    Bloomberg Video2 months ago

    Stada's CEO Says Top Line Growth Moved by New Products

    Oct.06 -- Claudio Albrecht, CEO at Stada Arzneimittel, discusses plans to take the company into new territory to build top line growth. He speaks on "Bloomberg Markets: European Open.."